The stock declined approximately 4.4% to HK$46.74 today, primarily driven by profit-taking following the prior strength fueled by biosimilar deal announcements and institutional rating upgrades. Morning session opened at HK$48.4, peaked at HK$49.12 around 9:36 AM, then retreated to close at HK$47.46; afternoon trading extended losses, reaching an intraday low of HK$46.38 at 3:47 PM before settling at HK$46.74. The stock has appreciated 43.64% year-to-date from HK$32.54, currently trading 19.4% below its 52-week high of HK$58, hovering near the 20-day moving average of HK$47.02. Recent quarterly results showed resilience: Q2 revenue reached HK$6.81 billion, up 24.83% year-over-year, while operating profit surged 44.25% to HK$2.15 billion with net margin stable at 20.7%. At a market capitalization of approximately HK$192.4 billion and a P/E multiple of 33.4, valuations appear fairly positioned relative to the strong momentum in its biotech drug and biosimilar services franchises.